Summit Corporation PLC: Summit to Present at the Canaccord Genuity 34th Annual Growth Conference

Summit Corporation PLC: Summit to Present at the Canaccord Genuity 34th Annual                               Growth Conference  Summit Corporation plc ('Summit' or the 'Company')  SUMMIT TO PRESENT COMPANY OVERVIEW AT THE CANACCORD GENUITY 34TH ANNUAL GROWTH CONFERENCE  Oxford, UK, 7 August 2014 - Summit (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection ('CDI'), announces that it will be presenting at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014, at 16:00 ET (21:00 BST). The conference will be held at the InterContinental Boston Hotel in Boston, MA.  Mr Glyn Edwards, Summit's Chief Executive Officer, will present a review of the Company's utrophin modulation programme for the treatment of the fatal muscle wasting disease DMD and he will also review Summit's selective antibiotic in development for the treatment of CDI.  A copy of the presentation will be available immediately after the event on the Investor Relations section of the Company's website, www.summitplc.com.                                     - END -  Notes to Editors  About Summit Summit is an Oxford, UK based drug discovery and development company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is quoted on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).  For more information, please contact:  Summit                               Tel: +44 (0)1235 443 939 Glyn Edwards / Richard Pye Cairn Financial Advisers LLP         Tel: +44 (0)20 7148 7900 (Nominated Adviser) Liam Murray / Tony Rawlinson N+1 Singer                           Tel: +44 (0)20 7496 3000 (Broker) Aubrey Powell / Jen Boorer Peckwater PR                         Tel: +44 (0)7879 458 364 (Financial public relations, UK)     tarquin.edwards@peckwaterpr.co.uk Tarquin Edwards MacDougall Biomedical Communications Tel: +1 781-235-3060 (US media contact)                   mavery@macbiocom.com Michelle Avery  ------------------------------------------------------------------------------  This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Summit Corporation PLC via Globenewswire HUG#1847074  
Press spacebar to pause and continue. Press esc to stop.